Research ArticleArticle
Open Access
Subcutaneously Administered Ofatumumab in Rheumatoid Arthritis: A Phase I/II Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics
Regina Kurrasch, Judith C. Brown, Myron Chu, Jenny Craigen, Philip Overend, Bela Patel, Steven Wolfe and David J. Chang
The Journal of Rheumatology June 2013, jrheum.121118; DOI: https://doi.org/10.3899/jrheum.121118
Regina Kurrasch
From GlaxoSmithKline (GSK), King of Prussia, Pennsylvania, USA; Stockley Park, UK; Stevenage, UK; and Research Triangle Park, North Carolina, USA. Sponsored by GlaxoSmithKline. R. Kurrasch, MD, MPH, GSK, King of Prussia, PA; J.C. Brown, PhD, GSK, Stockley Park, UK; M. Chu, DO, GSK, King of Prussia, Pennsylvania, USA; J. Craigen, PhD; P. Overend, BSc, GSK, Stevenage, UK; B. Patel, PhD, GSK, King of Prussia, PA; S. Wolfe, MS, GSK, Research Triangle Park, NC; D.J. Chang, MD, MPH, GSK, King of Prussia, PA. Address correspondence to Dr. R. Kurrasch, 2301 Renaissance Blvd., RN0320, King of Prussia, PA 19406, USA. E-mail: regina.h.kurrasch@gsk.com Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication March 27, 2013.
Judith C. Brown
From GlaxoSmithKline (GSK), King of Prussia, Pennsylvania, USA; Stockley Park, UK; Stevenage, UK; and Research Triangle Park, North Carolina, USA. Sponsored by GlaxoSmithKline. R. Kurrasch, MD, MPH, GSK, King of Prussia, PA; J.C. Brown, PhD, GSK, Stockley Park, UK; M. Chu, DO, GSK, King of Prussia, Pennsylvania, USA; J. Craigen, PhD; P. Overend, BSc, GSK, Stevenage, UK; B. Patel, PhD, GSK, King of Prussia, PA; S. Wolfe, MS, GSK, Research Triangle Park, NC; D.J. Chang, MD, MPH, GSK, King of Prussia, PA. Address correspondence to Dr. R. Kurrasch, 2301 Renaissance Blvd., RN0320, King of Prussia, PA 19406, USA. E-mail: regina.h.kurrasch@gsk.com Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication March 27, 2013.
Myron Chu
From GlaxoSmithKline (GSK), King of Prussia, Pennsylvania, USA; Stockley Park, UK; Stevenage, UK; and Research Triangle Park, North Carolina, USA. Sponsored by GlaxoSmithKline. R. Kurrasch, MD, MPH, GSK, King of Prussia, PA; J.C. Brown, PhD, GSK, Stockley Park, UK; M. Chu, DO, GSK, King of Prussia, Pennsylvania, USA; J. Craigen, PhD; P. Overend, BSc, GSK, Stevenage, UK; B. Patel, PhD, GSK, King of Prussia, PA; S. Wolfe, MS, GSK, Research Triangle Park, NC; D.J. Chang, MD, MPH, GSK, King of Prussia, PA. Address correspondence to Dr. R. Kurrasch, 2301 Renaissance Blvd., RN0320, King of Prussia, PA 19406, USA. E-mail: regina.h.kurrasch@gsk.com Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication March 27, 2013.
Jenny Craigen
From GlaxoSmithKline (GSK), King of Prussia, Pennsylvania, USA; Stockley Park, UK; Stevenage, UK; and Research Triangle Park, North Carolina, USA. Sponsored by GlaxoSmithKline. R. Kurrasch, MD, MPH, GSK, King of Prussia, PA; J.C. Brown, PhD, GSK, Stockley Park, UK; M. Chu, DO, GSK, King of Prussia, Pennsylvania, USA; J. Craigen, PhD; P. Overend, BSc, GSK, Stevenage, UK; B. Patel, PhD, GSK, King of Prussia, PA; S. Wolfe, MS, GSK, Research Triangle Park, NC; D.J. Chang, MD, MPH, GSK, King of Prussia, PA. Address correspondence to Dr. R. Kurrasch, 2301 Renaissance Blvd., RN0320, King of Prussia, PA 19406, USA. E-mail: regina.h.kurrasch@gsk.com Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication March 27, 2013.
Philip Overend
From GlaxoSmithKline (GSK), King of Prussia, Pennsylvania, USA; Stockley Park, UK; Stevenage, UK; and Research Triangle Park, North Carolina, USA. Sponsored by GlaxoSmithKline. R. Kurrasch, MD, MPH, GSK, King of Prussia, PA; J.C. Brown, PhD, GSK, Stockley Park, UK; M. Chu, DO, GSK, King of Prussia, Pennsylvania, USA; J. Craigen, PhD; P. Overend, BSc, GSK, Stevenage, UK; B. Patel, PhD, GSK, King of Prussia, PA; S. Wolfe, MS, GSK, Research Triangle Park, NC; D.J. Chang, MD, MPH, GSK, King of Prussia, PA. Address correspondence to Dr. R. Kurrasch, 2301 Renaissance Blvd., RN0320, King of Prussia, PA 19406, USA. E-mail: regina.h.kurrasch@gsk.com Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication March 27, 2013.
Bela Patel
From GlaxoSmithKline (GSK), King of Prussia, Pennsylvania, USA; Stockley Park, UK; Stevenage, UK; and Research Triangle Park, North Carolina, USA. Sponsored by GlaxoSmithKline. R. Kurrasch, MD, MPH, GSK, King of Prussia, PA; J.C. Brown, PhD, GSK, Stockley Park, UK; M. Chu, DO, GSK, King of Prussia, Pennsylvania, USA; J. Craigen, PhD; P. Overend, BSc, GSK, Stevenage, UK; B. Patel, PhD, GSK, King of Prussia, PA; S. Wolfe, MS, GSK, Research Triangle Park, NC; D.J. Chang, MD, MPH, GSK, King of Prussia, PA. Address correspondence to Dr. R. Kurrasch, 2301 Renaissance Blvd., RN0320, King of Prussia, PA 19406, USA. E-mail: regina.h.kurrasch@gsk.com Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication March 27, 2013.
Steven Wolfe
From GlaxoSmithKline (GSK), King of Prussia, Pennsylvania, USA; Stockley Park, UK; Stevenage, UK; and Research Triangle Park, North Carolina, USA. Sponsored by GlaxoSmithKline. R. Kurrasch, MD, MPH, GSK, King of Prussia, PA; J.C. Brown, PhD, GSK, Stockley Park, UK; M. Chu, DO, GSK, King of Prussia, Pennsylvania, USA; J. Craigen, PhD; P. Overend, BSc, GSK, Stevenage, UK; B. Patel, PhD, GSK, King of Prussia, PA; S. Wolfe, MS, GSK, Research Triangle Park, NC; D.J. Chang, MD, MPH, GSK, King of Prussia, PA. Address correspondence to Dr. R. Kurrasch, 2301 Renaissance Blvd., RN0320, King of Prussia, PA 19406, USA. E-mail: regina.h.kurrasch@gsk.com Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication March 27, 2013.
David J. Chang
From GlaxoSmithKline (GSK), King of Prussia, Pennsylvania, USA; Stockley Park, UK; Stevenage, UK; and Research Triangle Park, North Carolina, USA. Sponsored by GlaxoSmithKline. R. Kurrasch, MD, MPH, GSK, King of Prussia, PA; J.C. Brown, PhD, GSK, Stockley Park, UK; M. Chu, DO, GSK, King of Prussia, Pennsylvania, USA; J. Craigen, PhD; P. Overend, BSc, GSK, Stevenage, UK; B. Patel, PhD, GSK, King of Prussia, PA; S. Wolfe, MS, GSK, Research Triangle Park, NC; D.J. Chang, MD, MPH, GSK, King of Prussia, PA. Address correspondence to Dr. R. Kurrasch, 2301 Renaissance Blvd., RN0320, King of Prussia, PA 19406, USA. E-mail: regina.h.kurrasch@gsk.com Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication March 27, 2013.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Subcutaneously Administered Ofatumumab in Rheumatoid Arthritis: A Phase I/II Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics
Regina Kurrasch, Judith C. Brown, Myron Chu, Jenny Craigen, Philip Overend, Bela Patel, Steven Wolfe, David J. Chang
The Journal of Rheumatology Jun 2013, jrheum.121118; DOI: 10.3899/jrheum.121118
Subcutaneously Administered Ofatumumab in Rheumatoid Arthritis: A Phase I/II Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics
Regina Kurrasch, Judith C. Brown, Myron Chu, Jenny Craigen, Philip Overend, Bela Patel, Steven Wolfe, David J. Chang
The Journal of Rheumatology Jun 2013, jrheum.121118; DOI: 10.3899/jrheum.121118